Drugs / ¹⁷⁷Lu-HT547
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07639970 | Jun 2026 → Jun 2027 expected | breast cancer, glioma, head and neck cancer, malignant pancreatic neoplasm | Hua Pang | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ¹⁷⁷Lu-HT547 | “Subsequently, a single intravenous dose (approximately 4 GBq) of ¹⁷⁷Lu-HT547 will be administered for follow-up SPECT/CT imaging and dosimetry studies.” NCT07639970 ↗ |
| Modality | Diagnostic / imaging agent | “¹⁷⁷Lu-HT547 will be administered for follow-up SPECT/CT imaging and dosimetry studies” NCT07639970 ↗ |
| Route | Intravenous | “a single intravenous dose (approximately 4 GBq) of ¹⁷⁷Lu-HT547” NCT07639970 ↗ |